HUTCHMED DRC (HCM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $2.59B
Last updated: Nov 17, 2026 at 11:05 AM ET
HUTCHMED DRC (HCM) Financials: Revenue, Profit and Cash Flow
HUTCHMED DRC reported revenue of $549.96M for the fiscal year ended Dec 31, 2025, down 12.7% from the year before. That year, net income was $458.12M with a net margin of 83.3%, operating cash flow was -$64.66M and free cash flow was -$88.81M. The quarter ended Jun 30, 2026 had revenue of $139.14M and net income of $7.96M.
Revenue and Margins
The operating margin was -10.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $216.08M, a compound annual rate of 10.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $549.96M | -12.7% | 38.7% | -10.0% | 83.3% |
| Dec 2024 | $630.20M | -24.8% | 44.8% | -6.9% | 6.0% |
| Dec 2023 | $838.00M | +96.5% | 54.1% | 2.2% | 12.0% |
| Dec 2022 | $426.41M | +19.7% | 27.0% | -168.6% | -84.6% |
| Dec 2021 | $356.13M | +55.9% | 91.9% | -100.3% | -54.7% |
| Dec 2020 | $228.37M | +11.5% | 17.3% | -87.0% | -55.2% |
| Dec 2019 | $204.89M | -4.3% | 21.8% | -74.6% | -51.7% |
| Dec 2018 | $214.11M | -11.2% | 32.8% | -43.3% | -34.9% |
| Dec 2017 | $241.20M | +11.6% | 27.1% | -22.1% | -11.1% |
| Dec 2016 | $216.08M | N/A | 27.7% | -21.6% | 5.4% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1114.2% from the year before. In the quarter ended Jun 2026, net income fell 96.5% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $549.96M | $630.20M | $838.00M | $426.41M | $356.13M | $228.37M | $204.89M | $214.11M | $241.20M | $216.08M |
| Cost of revenue | $337.24M | $347.63M | $384.45M | $311.10M | $28.79M | $188.84M | $160.15M | $143.94M | $175.82M | $156.33M |
| Gross profit | $212.72M | $282.57M | $453.55M | $115.31M | $327.34M | $39.52M | $44.74M | $70.17M | $65.38M | $59.75M |
| Research and development | $164.15M | $213.37M | $303.06M | $386.89M | $299.09M | $176.69M | $91.94M | $115.58M | $75.78M | $66.87M |
| Operating income | -$54.73M | -$43.70M | $18.38M | -$718.80M | -$357.10M | -$198.62M | -$152.78M | -$92.64M | -$53.42M | -$46.70M |
| Net income | $458.12M | $37.73M | $100.78M | -$360.83M | -$194.65M | -$125.95M | -$106.02M | -$74.81M | -$26.74M | $11.70M |
| EBITDA | -$41.42M | -$31.36M | $26.58M | -$351.35M | -$147.34M | -$192.56M | -$135.13M | -$82.06M | -$49.50M | -$43.36M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $139.14M | $139.14M | $135.42M | $135.42M | $138.84M | $138.84M | $162.26M | $162.26M | $152.84M | $152.84M | $152.56M | $80.25M |
| Gross profit | $23.67M | $23.67M | -$23.12M | -$23.12M | $55.05M | $55.05M | -$28.17M | -$28.17M | $62.77M | $62.77M | -$86.50M | -$86.50M |
| Operating income | $434.50K | $434.50K | -$17.82M | -$17.82M | -$1.76M | -$1.76M | -$8.09M | -$8.09M | -$13.76M | -$13.76M | -$46.64M | -$46.64M |
| Net income | $7.96M | $7.96M | $977.50K | $977.50K | $227.48M | $227.48M | $5.96M | $5.96M | $12.90M | $12.90M | -$33.89M | -$33.89M |
Balance Sheet
As of Dec 2025, total debt of $96.04M exceeded cash and equivalents by $24.71M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.75B | $1.27B | $1.28B | $1.03B | $1.37B | $724.12M | $465.12M | $532.12M | $597.93M | $342.44M |
| Current assets | $1.57B | $1.07B | $1.10B | $839.89M | $1.21B | $530.74M | $317.02M | $370.54M | $432.19M | $167.38M |
| Cash and equivalents | $71.33M | $153.96M | $283.59M | $313.28M | $377.54M | $235.63M | $121.16M | $86.04M | $85.27M | $79.43M |
| Total liabilities | $501.84M | $502.34M | $536.39M | $392.57M | $333.15M | $205.17M | $152.22M | $119.86M | $112.97M | $138.38M |
| Short-term debt | $27.85M | $26.30M | $35.08M | $3.71M | $31.82M | $5.97M | $3.58M | $432.00K | $31.99M | $22.19M |
| Long-term debt | $68.19M | $59.43M | $48.19M | $18.10M | $0 | $26.86M | $26.82M | $26.74M | $0 | $26.83M |
| Shareholder equity | $1.24B | $759.93M | $730.54M | $610.37M | $986.89M | $484.12M | $288.01M | $389.00M | $461.73M | $184.27M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.74B | $1.74B | $1.75B | $1.75B | $1.78B | $1.78B | $1.27B | $1.27B | $1.26B | $1.26B | $1.28B | $1.28B |
| Total liabilities | $461.46M | $461.46M | $501.83M | $501.83M | $534.02M | $534.02M | $502.34M | $502.34M | $508.85M | $508.85M | $536.39M | $536.39M |
| Cash and equivalents | $106.56M | $106.56M | $71.33M | $71.33M | $110.72M | $110.72M | $153.96M | $153.96M | $203.95M | $203.95M | $283.59M | $283.59M |
| Shareholder equity | $1.26B | $1.26B | $1.24B | $1.24B | $1.23B | $1.23B | $759.93M | $759.93M | $740.08M | $740.08M | $730.54M | $730.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.66M | $497.00K | $219.26M | -$268.60M | -$204.22M | -$62.07M | -$80.91M | -$32.85M | -$8.94M | -$9.57M |
| Capital expenditures | $24.15M | $17.93M | $32.61M | $36.66M | $16.76M | $19.58M | $8.56M | $6.36M | $5.02M | $4.33M |
| Free cash flow | -$88.81M | -$17.44M | $186.65M | -$305.26M | -$220.98M | -$81.65M | -$89.48M | -$39.21M | -$13.96M | -$13.90M |
| Dividends paid | N/A | N/A | $123.41M | $87.44M | $99.74M | $35.00K | $28.14M | $24.90M | $55.59M | $11.66M |
| Investing cash flow | -$29.41M | -$96.06M | -$291.14M | $296.59M | -$306.32M | -$125.44M | $119.03M | $43.75M | -$260.78M | -$33.60M |
| Financing cash flow | $7.84M | -$30.67M | $48.66M | -$82.76M | $650.03M | $296.43M | -$1.49M | -$8.23M | $273.20M | $92.44M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.11M | $6.11M | $4.12M | $4.12M | -$36.45M | -$36.45M | $20.16M | $20.16M | -$19.92M | -$19.92M | -$3.57M | -$3.57M |
| Capital expenditures | $2.81M | $2.81M | $2.44M | $2.44M | $4.63M | $4.63M | $3.91M | $3.91M | $5.05M | $5.05M | $4.13M | $4.13M |
| Free cash flow | $3.30M | $3.30M | $1.68M | $1.68M | -$41.08M | -$41.08M | $16.25M | $16.25M | -$24.97M | -$24.97M | -$7.70M | -$7.70M |
Frequently Asked Questions About HCM
What is HUTCHMED DRC's annual revenue?
HUTCHMED DRC reported revenue of $549.96M for the fiscal year ended Dec 31, 2025.
How fast is HUTCHMED DRC's revenue growing?
Revenue was down 12.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.9%.
Is HUTCHMED DRC profitable?
Yes. HUTCHMED DRC reported net income of $458.12M for the fiscal year ended Dec 31, 2025, with a net margin of 83.3%.
How much free cash flow does HCM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$64.66M minus capital expenditures of $24.15M produced free cash flow of -$88.81M.
How much debt does HUTCHMED DRC have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $68.19M, short-term debt of $27.85M and cash and equivalents of $71.33M.
HCM pages: Overview, Financials